Develops biological medicines for hematology. Manufactures biological medicines for clinical immunology. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 2.1× for every dollar of annual revenue.
No analyst target is on record for this company.
The stock trades 34% below its peak. The market has trimmed its expectations for the company.
It pays out $0.05 per share each year — regular cash for whoever holds the stock.
A loss of $82.0M against $752.6M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.